FDA Approves AstraZeneca's Etcamah for HR-Positive Breast Cancer with ESR1 Mutation

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the first-line treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer. This approval is specifically for cases where an ESR1 mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy, based on results from the SERENA-6 Phase III trial.